Toxins for Antibody-Drug Conjugate Research Library
生物活性
Eribulin (E7389) is a microtubule targeting agent that is used for the research of metastatic breast cancer. Eribulin inhibits the proliferation of cancer cells by binding microtubule proteins and microtubules.
体外研究 (In Vitro)
Eribulin (1-100 nM; 72 h) inhibits cells proliferation, with IC50s of 22.8 and 21.5 nM for LM8 and Dunn cells, respectively[1]. Eribulin (10-50 nM; 12-72 h) increases early apoptosis significantly after 24 h treatment at the dose of 50 nM in LM8 cells[1]. Eribulin (10-50 nM; 12-72 h) induces G2/M arrest by 12 h treatment with at the dose of 50 nM, but not by long-term treatment (72 h) with 10 nM in LM8 cells[1]. Eribulin (1-50 nM; 12 h) does not induce senescence in LM8 cells[1]. Eribulin (1-10 nM; 16 h) induces morphological change and suppresses cell migration in a low concentration in LM8 cells[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay[1]
Cell Line:
LM8 cells and Dunn cells
Concentration:
0, 1, 10, 100 nM
Incubation Time:
72 hours
Result:
Inhibited cells proliferation in a dose-dependent manner.
Apoptosis Analysis[1]
Cell Line:
LM8 cells
Concentration:
0, 10, 50 nM
Incubation Time:
12, 24, 48, 72 hours
Result:
Induced early apoptosis after 12 h at the concentration of 50 nM. Not detected apoptosis at the concentration of 10 nM.
Cell Cycle Analysis[1]
Cell Line:
LM8 cells
Concentration:
0, 10, 50 nM
Incubation Time:
12, 24, 48, 72 hours
Result:
Induced G2/M arrest by 12 h treatment with 50 nM. No G2/M arrest was induced by10 nM treatment.
体内研究 (In Vivo)
Eribulin (1 mg/kg; i.v. once a week for 2 weeks) reduces primary tumor growth and lung metastasis of osteosarcoma in mice[1]. Eribulin (1 mg/kg; once i.v.) suppresses circulating tumor cells (CTC) appearance in the low-concentration phase[1].
上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Model:
C3H/HeN mice (4-week-old) are injected LM8 cells[1]
Dosage:
1 mg/kg
Administration:
I.v. once a week for 2 weeks
Result:
Suppressed primary tumor growth and induced apoptosis in tumor cells. Reduced lung metastasis. Decreased the body weights.
Clinical Trial
分子量
729.90
Formula
C40H59NO11
CAS 号
253128-41-5
中文名称
艾日布林
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
4°C, protect from light, stored under nitrogen
*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
参考文献
[1]. Watanabe K, et, al. Low-dose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo. Oncotarget. 2019 Jan 4; 10(2): 161-174.
[2]. Okouneva, T., et al., Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase. Mol Cancer Ther, 2008. 7(7): p. 2003-11.
[3]. Smith, J.A., et al., Eribulin binds at microtubule ends to a single site on tubulin to suppress dynamic instability. Biochemistry, 2010. 49(6): p. 1331-7.
[4]. Towle, M.J., et al., Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res, 2011. 71(2): p. 496-505.
